BIGBEAR
PHARMACEUTICAL
Osimertinib is a third-generation targeted therapy for lung cancer, specifically designed to treat non-small cell lung cancer driven by specific genetic mutations.
AuthenticGuaranteeFast DeliveryPrivacy Since its FDA approval in the United States in 2015, Osimertinib has been widely used and recognized globally. In China, Osimertinib is marketed and i···【More】
Update: 06 Mar,2026Source: BigbearViews: 149
Osimertinib is a targeted therapy, belonging to the third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors.Side effects r···【More】
Update: 06 Mar,2026Source: BigbearViews: 136
Osimertinib, as a third-generation EGFR-TKI, has become a breakthrough drug in the treatment of non-small cell lung cancer (NSCLC) due to its highly e···【More】
Update: 06 Mar,2026Source: BigbearViews: 136
On April 18, 2018, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) had approved osimertinib for first-line treatment of patient···【More】
Update: 06 Mar,2026Source: BigbearViews: 130
On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to osimertinib for the treatment of patients with advan···【More】
Update: 06 Mar,2026Source: BigbearViews: 141
Osimertinib is a targeted therapy for non-small cell lung cancer. Common side effects include skin reactions (rash, dryness), gastrointestinal discomf···【More】
Update: 06 Mar,2026Source: BigbearViews: 135
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
